Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest news, analyses and commentary where available.